FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma

Leukemia

Volumn 28, Issue 12, 2014, Pages 2376-2387

  Sehgal, L ^a   Mathur, R ^a   Braun, F K ^a   Wise, J F ^a   Berkova, Z ^a   Neelapu, S ^a   Kwak, L W ^a   Samaniego, F ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY RNA; FAS ANTISENSE 1 PROTEIN; FAS RECEPTOR; IBRUTINIB; LONG UNTRANSLATED RNA; MESSENGER RNA PRECURSOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; EZH2 PROTEIN, HUMAN; FAS ANTIGEN; FAS LIGAND; HISTONE; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN BINDING; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; RBM5 PROTEIN, HUMAN; RNA BINDING PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ALTERNATIVE RNA SPLICING; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; GENE CONTROL; GENE REPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UPREGULATION; APOPTOSIS; BIOLOGICAL MODEL; BLOOD; DNA METHYLATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; INTRON; METABOLISM; TUMOR CELL LINE;

ALTERNATIVE SPLICING; ANTIGENS, CD95; APOPTOSIS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DNA METHYLATION; DNA-BINDING PROTEINS; FAS LIGAND PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HISTONES; HUMANS; INTRONS; LYMPHOMA, B-CELL; MODELS, BIOLOGICAL; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN BINDING; PYRAZOLES; PYRIMIDINES; RNA, ANTISENSE; RNA, LONG NONCODING; RNA-BINDING PROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 84922380590     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.126     Document Type: Article

References (62)

1. Nagata S. Fas and Fas ligand: a death factor and its receptor. Adv Immunol 1994; 57: 129-144.
2. Xerri L, Bouabdallah R, Devilard E, Hassoun J, Stoppa AM, Birg F. Sensitivity to Fas-mediated apoptosis is null or weak in B-cell non-Hodgkin's lymphomas and is moderately increased by CD40 ligation. Br J Cancer 1998; 78: 225-232.
3. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-1462.
4. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000; 21: 485-495.
5. Rudin CM, Thompson CB. Apoptosis and disease: regulation and clinical relevance of programmed cell death. Annu Rev Med 1997; 48: 267-281.
6. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.
7. Eichhorst ST, Muerkoster S, Weigand MA, Krammer PH. The chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse thymocytes in vivo via activation of the CD95(APO-1/Fas) system. Cancer Res 2001; 61: 243-248.
8. Friesen C, Fulda S, Debatin KM. Induction of CD95 ligand and apoptosis by doxorubicin is modulated by the redox state in chemosensitive- and drugresistant tumor cells. Cell Death Differ 1999; 6: 471-480.
9. Friesen C, Fulda S, Debatin KM. Cytotoxic drugs and the CD95 pathway. Leukemia 1999; 13: 1854-1858.
10. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996; 2: 574-577.
11. Lee SH, Kim SY, Lee JY, Shin MS, Dong SM, Na EY et al. Detection of soluble Fas mRNA using in situ reverse transcription-polymerase chain reaction. Lab Invest 1998; 78: 453-459.
12. Bonnal S, Martinez C, Forch P, Bachi A, Wilm M, Valcarcel J. RBM5/Luca-15/H37 regulates Fas alternative splice site pairing after exon definition. Mol Cell 2008; 32: 81-95.
13. Aratake K, Kamachi M, Iwanaga N, Kawasaki E, Izumi Y, Ida H et al. A cross-talk between RNA splicing and signaling pathway alters Fas gene expression at posttranscriptional level: alternative splicing of Fas mRNA in the leukemic U937 cells. J Lab Clin Med 2005; 146: 184-191.
14. Kotlajich MV, Hertel KJ. Death by splicing: tumor suppressor RBM5 freezes splicesite pairing. Mol Cell 2008; 32: 162-164.
15. Hara T, Tsurumi H, Takemura M, Goto H, Yamada T, Sawada M et al. Serum-soluble fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma. Am J Hematol 2000; 64: 257-261.
16. Yufu Y, Choi I, Hirase N, Tokoro A, Noguchi Y, Goto T et al. Soluble Fas in the serum of patients with non-Hodgkin's lymphoma: higher concentrations in angioimmunoblastic T-cell lymphoma. Am J Hematol 1998; 58: 334-336.
17. Kanda Y, Chiba S, Tanaka Y, Kami M, Saito T, Izutsu K et al. Increased serum soluble Fas ligand associated with recurrent B-cell non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation. Leuk Lymphoma 1999; 34: 625-628.
18. Niitsu N, Sasaki K, Umeda M. A high serum soluble Fas/APO-1 level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma. Leukemia 1999; 13: 1434-1440.
19. Papoff G, Cascino I, Eramo A, Starace G, Lynch DH, Ruberti G. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J Immunol 1996; 156: 4622-4630.
20. Wise JF, Berkova Z, Mathur R, Zhu H, Braun FK, Tao RH et al. Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex. Blood 2013; 121: 4729-4739.
21. Khapare N, Kundu ST, Sehgal L, Sawant M, Priya R, Gosavi P et al. Plakophilin3 loss leads to an increase in PRL3 levels promoting K8 dephosphorylation, which is required for transformation and metastasis. PLoS One 2012; 7: e38561.
22. Yan MD, Hong CC, Lai GM, Cheng AL, Lin YW, Chuang SE. Identification and characterization of a novel gene Saf transcribed from the opposite strand of Fas. Hum Mol Genet 2005; 14: 1465-1474.
23. Beltran M, Puig I, Pena C, Garcia JM, Alvarez AB, Pena R et al. A natural antisense transcript regulates Zeb2/Sip1 gene expression during Snail1-induced epithelialmesenchymal transition. Genes Dev 2008; 22: 756-769.
24. Kouzarides T. Histone methylation in transcriptional control. Curr Opin Genet Dev 2002; 12: 198-209.
25. Pasini D, Bracken AP, Jensen MR, Lazzerini Denchi E, Helin K. Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. EMBO J 2004; 23: 4061-4071.
26. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004; 6: 1-6.
27. Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera R, Califano A. Reverse engineering of regulatory networks in human B cells. Nat Genet 2005; 37: 382-390.
28. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603-607.
29. Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 2008; 112: 4202-4212.
30. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007; 21: 1050-1063.
31. Sutherland LC, Rintala-Maki ND, White RD, Morin CD. RNA binding motif (RBM) proteins: a novel family of apoptosis modulators? J Cell Biochem 2005; 94: 5-24.
32. Bellucci M, Agostini F, Masin M, Tartaglia GG. Predicting protein associations with long noncoding RNAs. Nat Methods 2011; 8: 444-445.
33. Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol 2013; 34: 592-601.
34. Ghosh AK, Kay NE. Critical signal transduction pathways in CLL. Adv Exp Med Biol 2013; 792: 215-239.
35. Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci 2010; 107: 13075-13080.
36. Staudt LM, Dunleavy K, Buggy JJ, Hedrick E, Lucas N, Pittaluga S et al. Bruton's tyrosine kinase (Btk) the inhibitor PCI-32765 modulates chronic active BCR signaling and induces tumor regression in relapsed/refractory ABC DLBCL. Blood 2011; 118: 1168-1169.
37. Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 2010; 7: 299-313.
38. Beguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 2013; 23: 677-692.
39. Velichutina I, Shaknovich R, Geng H, Johnson NA, Gascoyne RD, Melnick AM et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 2010; 116: 5247-5255.
40. Chang CJ, Hung MC. The role of EZH2 in tumour progression. Br J Cancer 2012; 106: 243-247.
41. Wrench D, Sangaralingam A, Tayyib H, Kang MK, Riain C, Gupta M et al. TNFRSF14 and EZH2 mutations, Chr2p gain and copy number changes targeting genes whose proteins interact with the microenvironment in transformed follicular lymphoma. Blood 2010; 116: 349-349.
42. Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin Cancer Res 2011; 17: 2613-2618.
43. Yap DB, Chu J, Berg T, Schapira M, Cheng SW, Moradian A et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2011; 117: 2451-2459.
44. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012; 492: 108-112.
45. Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 2012; 8: 890-896.
46. Fiskus W, Rao R, Balusu R, Ganguly S, Tao J, Sotomayor E et al. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells. Clin Cancer Res 2012; 18: 6227-6238.
47. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005; 5: 251-262.
48. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010; 463: 88-92.
49. Wiestner A. Targeting B-cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol 2013; 31: 128-130.
50. Hudson R. Odor and odorant: a terminological clarification. Chem Senses 2000; 25: 693.
51. Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011; 117: 6287-6296.
52. Kondo E, Yoshino T. Expression of apoptosis regulators in germinal centers and germinal center-derived B-cell lymphomas: insight into B-cell lymphomagenesis. Pathol Int 2007; 57: 391-397.
53. Timmer T, de Vries EG, de Jong S. Fas receptor-mediated apoptosis: a clinical application? J Pathol 2002; 196: 125-134.
54. Lynch DH, Watson ML, Alderson MR, Baum PR, Miller RE, Tough T et al. The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity 1994; 1: 131-136.
55. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995; 268: 1347-1349.
56. Muller M, Scaffidi CA, Galle PR, Stremmel W, Krammer PH. The role of p53 and the CD95 (APO-1/Fas) death system in chemotherapy-induced apoptosis. Eur Cytokine Netw 1998; 9: 685-686.
57. Poulaki V, Mitsiades CS, Mitsiades N. The role of Fas and FasL as mediators of anticancer chemotherapy. Drug Resist Updat 2001; 4: 233-242.
58. Wang W, Cassidy J, O'Brien V, Ryan KM, Collie-Duguid E. Mechanistic and predictive profiling of 5-fluorouracil resistance in human cancer cells. Cancer Res 2004; 64: 8167-8176.
59. Oh JJ, Grosshans DR, Wong SG, Slamon DJ. Identification of differentially expressed genes associated with HER-2/neu overexpression in human breast cancer cells. Nucleic Acids Res 1999; 27: 4008-4017.
60. Berkova Z, Wang S, Wise JF, Maeng H, Ji Y, Samaniego F. Mechanism of Fas signaling regulation by human herpesvirus 8 K1 oncoprotein. J Natl Cancer Inst 2009; 101: 399-411.
61. Mielgo A, van Driel M, Bloem A, Landmann L, Gunthert U. A novel antiapoptotic mechanism based on interference of Fas signaling by CD44 variant isoforms. Cell Death Differ 2006; 13: 465-477.
62. Wang S, Wang S, Maeng H, Young DP, Prakash O, Fayad LE et al. K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis. Blood 2007; 109: 2174-2182.